SI
ORIC icon

Sofinnova Investments’s Oric Pharmaceuticals ORIC Stock Holding History

Sofinnova Investments’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-679,578
Closed -$8.61M – 75
2026
Q1 		$8.61M Buy
+679,578
New +$7.71M 0.33% 48
2020
Q3 		– Sell
-17,369
Closed -$585K – 81
2020
Q2 		$585K Buy
+17,369
New +$554K 0.04% 75

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sofinnova Investments's ORIC Position: Q2 2026 in Review

Sofinnova Investments sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 679,578 shares — an estimated $8.61M sold.

Sofinnova Investments first reported a position in ORIC in Q2 2020 and held it in 2 quarters. The position peaked at $8.61M in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Sofinnova Investments reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Sofinnova Investments sold 679,578 Oric Pharmaceuticals shares in Q2 2026, an estimated $8.61M.
  • Sofinnova Investments first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Sofinnova Investments's Oric Pharmaceuticals position peaked at $8.61M in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Sofinnova Investments's 13F filing for Q2 2026, filed 14 Aug 2026.